Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 2: Checkpoint Inhibitor Therapy for Microsatellite Instability-High and Microsatellite-Stable Endometrial Cancer — Dr Birrer CME information and select publications

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 3: Current Indications and Future Role of Immune Checkpoint Inhibitors in Cervical Cancer — Dr Tewari CME information and select publications

Data + Perspectives: The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers — Faculty Presentation 4: Novel Targeted Agents and Strategies Under Investigation for Gynecologic Cancers — Dr O’Malley CME information and select publications

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Michael J Birrer, Ursula Matulonis, David M O’Malley and Krishnansu S Tewari.

• Molecular subtypes of endometrial cancer and response to immune checkpoint inhibitors; testing for mismatch repair deficiency and POLE mutations (00:00)
• Integration of immune checkpoint inhibitors into the management of endometrial cancer (10:31)
• Efficacy and tolerability of anti-PD-1/PD-L1 antibodies for endometrial cancer; incorporation of pembrolizumab/lenvatinib into the treatment algorithm (17:24)
• Activity of immune checkpoint inhibitors alone and in combination with chemotherapy for cervical cancer; results from the JAVELIN Ovarian 100 trial evaluating avelumab as first-line therapy for ovarian cancer (29:16)
• Role of immune checkpoint inhibitors in the first- and second-line settings for patients with metastatic cervical cancer; perspective on hyperprogression and pseudoprogression (40:38)
• Emerging data with immune checkpoint inhibitors in combination with chemotherapy or PARP inhibitors for ovarian cancer; recent guidelines regarding mismatch repair deficiency testing (53:07)
• Mechanism of action, dosing and ongoing evaluation of dostarlimab for advanced or recurrent endometrial cancer (57:07)
• Novel antibody-drug conjugate tisotumab vedotin under investigation for gynecologic cancers (1:02:55)
• Side effects associated with tisotumab vedotin (1:09:56)
• Challenges with immunotherapy for patients with gynecologic cancers in the COVID-19 era (1:16:20)
• Impact of COVID-19 on clinical research for patients with gynecologic cancers (1:22:13)

CME information and select publications

Proceedings from the first in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Virginia Kaklamani, Ms Marissa Marti, Dr Joyce O’Shaughnessy and Mr Daniel G Pizana.

• Introduction (00:00)
• Neoadjuvant therapy for patients with localized HER2-positive breast cancer (2:20)
• Activity and tolerability of T-DM1 as adjuvant therapy (7:24)
• Clinical experience with neratinib as postadjuvant therapy for patients with HER2-positive breast cancer (11:00)
• Results of the KATHERINE study comparing T-DM1 to trastuzumab and the APHINITY trial evaluating pertuzumab, trastuzumab and chemotherapy as adjuvant therapy for HER2-positive early breast cancer (15:48)
• Benefits and risks with the novel agents trastuzumab deruxtecan and tucatinib for HER2-positive metastatic breast cancer (mBC) (26:13)
• Role of the immune checkpoint inhibitors atezolizumab and pembrolizumab and the novel antibody-drug conjugate sacituzumab govitecan for triple-negative breast cancer (38:49)
• Genomic testing for patients with breast cancer; integration of PARP inhibitors into the therapeutic algorithm for patients with mBC and germline BRCA mutations (52:59)
• Efficacy and tolerability of the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib for ER-positive, HER2-negative mBC (1:07:56)
• Activity of alpelisib in patients with ER-positive mBC and PIK3CA mutations; results of the SOLAR-1 trial evaluating alpelisib with fulvestrant (1:16:19)

CNE information and select publications